Literature DB >> 2981408

Hepatitis B virus DNA in patients with chronic liver disease and negative tests for hepatitis B surface antigen.

C Bréchot, F Degos, C Lugassy, V Thiers, S Zafrani, D Franco, H Bismuth, C Trépo, J P Benhamou, J Wands.   

Abstract

We assessed the presence of hepatitis B virus (HBV) DNA in liver or serum samples from 134 patients with hepatitis B surface antigen (HBsAg)-negative chronic liver disease, including 20 with hepatocellular carcinoma. HBV DNA sequences were detected in 52 of the 88 liver samples (59 per cent), including 17 of the 20 samples from patients with hepatocellular carcinoma. Presumably "replicative forms" of HBV DNA were detected in only 5 of the 88 liver samples, 3 of which were from patients with no serologic marker for HBV. In most of the liver samples the DNA patterns were consistent with the presence of HBV or a closely related virus. Of the 105 serum samples tested, HBV DNA sequences were identified in 10 (9.5 per cent), 6 of which had no HBV serologic marker. Moreover, HBsAg-associated determinants were detected in 5 of 17 patients who were positive for HBV DNA and in none of 14 patients who were negative. This study demonstrates the high frequency of HBsAg-negative HBV DNA-positive viral infection of the liver and suggests that multiplication of HBV may occur in the absence of any conventional serologic marker for HBV.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2981408     DOI: 10.1056/NEJM198501313120503

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  69 in total

1.  Reappearance of hepatitis B surface antigen in immunocompromised individuals: reinfection or reactivation?

Authors:  Keisuke Hino; Ashraf A Basuni; Jacqueline Ireland; Antony Newell; Jeffrey Mphahlele; Erasmus J Smit; Siew Lin Ngui; Chong Gee Teo; William F Carman
Journal:  Dig Dis Sci       Date:  2002-02       Impact factor: 3.199

2.  A novel stop codon mutation in HBsAg gene identified in a hepatitis B virus strain associated with cryptogenic cirrhosis.

Authors:  Xu Yang; Xiao-Peng Tang; Jian-Hua Lei; Hong-Yu Luo; Yong-Hong Zhang
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

3.  Effects of interferon-alpha therapy on serum and liver HBV DNA in patients with chronic hepatitis B.

Authors:  S V Feinman; B Berris; R Sooknanan; B Fernandes; S Bojarski
Journal:  Dig Dis Sci       Date:  1992-10       Impact factor: 3.199

4.  Reactivation of hepatitis B virus in a previously immune patient with human immunodeficiency virus infection.

Authors:  B Vandercam; C Cornu; J L Gala; A Geubel; M Cahill; M E Lamy
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-09       Impact factor: 3.267

5.  Primary hepatocellular carcinoma following nonspecific non-B hepatitis with tumor DNA negative for HBV DNA.

Authors:  E B Cohen; D L Gang; J B Zeldis
Journal:  Dig Dis Sci       Date:  1987-12       Impact factor: 3.199

Review 6.  Hepatocellular carcinoma. A worldwide problem and the major risk factors.

Authors:  R G Simonetti; C Cammà; F Fiorello; F Politi; G D'Amico; L Pagliaro
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

Review 7.  Diagnosis and management of clinical and subclinical cobalamin deficiency: advances and controversies.

Authors:  Ralph Carmel; Mona Sarrai
Journal:  Curr Hematol Rep       Date:  2006-03

8.  HBV-DNA-related hepatocellular carcinoma occurring in childhood. Report of three cases.

Authors:  R Giacchino; C Navone; F Facco; G Giambartolomei; P Pontisso; F Callea
Journal:  Dig Dis Sci       Date:  1991-08       Impact factor: 3.199

9.  Geographical variation in prevalence of hepatitis B virus DNA in HBsAg negative patients.

Authors:  Y M Lo; E S Lo; W Z Mehal; M Sampietro; G Fiorelli; G Ronchi; C H Tse; K A Fleming
Journal:  J Clin Pathol       Date:  1993-04       Impact factor: 3.411

10.  Woodchuck hepatitis virus X protein is required for viral infection in vivo.

Authors:  F Zoulim; J Saputelli; C Seeger
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.